mt-HIGH patients have expression profiles characterized by metastatic programs and the cytoprotective outcomes of mitohormesis. While mitohormesis is associated with health and longevity in non-pathological settings, these results indicate that it is perniciously used by cancer cells to promote tumor progression.
In Brief
Mitohormesis, a phenomenon resulting in persistent activation of cytoprotective mechanisms, has been studied in the context of aging and longevity. Kenny et al. demonstrate that breast cancer cells co-opt mitohormesis to promote their invasion and metastasis via activation of the mitochondrial unfolded protein response (UPR mt
INTRODUCTION
The Warburg effect has led to the misconception that the mitochondria of cancer cells are non-functional (Vander Heiden et al., 2009) . It is now recognized that they are, in fact, critical for tumor growth and exhibit drastic reprogramming to support the unique metabolic and biosynthetic needs of a cancer cell (Pavlova and Thompson, 2016; Vyas et al., 2016; Wallace, 2012) . Mitochondrial reprogramming is characterized by elevated oxidative stress via reactive oxygen species (ROS). As the majority of ROS are produced at the mitochondrial inner membrane, the mitochondria of cancer cells are especially prone to their effects. Increased ROS can serve as signaling molecules important for oncogenesis and tumor formation (D'Autré aux and Toledano, 2007; Schieber and Chandel, 2014) . On the other hand, ROS can damage lipids, DNA, and proteins by oxidation-causing protein misfolding. In metastatic cells, the effects of ROS may be exacerbated due to anchorage-independent growth and the foreign microenvironments experienced during dissemination. Excessive ROS poses a severe risk to mitochondrial network integrity and, in turn, cancer cell viability. These observations emphasize the need for cancer cells to maintain mitochondrial fitness through adaptive mechanisms, including proteostasis, antioxidant machinery, mitochondrial biogenesis, and mitophagy.
Hormesis describes the biphasic response of a cell or organism to increasing amounts of a substance or condition. At high doses, these toxins or stressors are determinantal, but at low level exposure within the ''hormetic zone,'' favorable biological responses are produced (Mattson, 2008) .
Mitochondrial ROS within the hormetic zone activates mitoprotective mechanisms, which paradoxically persist when the acute stress subsides-termed mitohormesis (Ristow and Zarse, 2010; Yun and Finkel, 2014) . Mitohormesis elicited by mitochondrial ROS extends lifespan in C. elegans and yeast (Bonawitz et al., 2007; Lee et al., 2010; Yang and Hekimi, 2010; Feng et al., 2001; Van Raamsdonk and Hekimi, 2009; Schulz et al., 2007) . In flies and worms, the mitochondrial unfolded protein response (UPR mt ) was identified as a pathway essential for mitohormesis-induced longevity (Dillin et al., 2002; Feng et al., 2001; Merkwirth et al., 2016; Tian et al., 2016; Owusu-Ansah et al., 2013; Nargund et al., 2015; Durieux et al., 2011) . The UPR mt was originally discovered by the Hoogenraad group, who described retrograde signaling mediated by C/EBP homologous protein (CHOP) leading to the induction of mitochondrial proteases, such as HSP60 (Zhao et al., 2002) . Using HSP60 as a UPR mt reporter in C. elegans, subsequent work has identified ATFS-1 and DVE-1/UBL5 as important transcriptional activators of the UPR mt (Benedetti et al., 2006; Durieux et al., 2011; Fiorese et al., 2016; Gitschlag et al., 2016; Haynes et al., 2007 Haynes et al., , 2010 Lin et al., 2016; Lisanti et al., 2016; Merkwirth et al., 2016; Nargund et al., 2015 Nargund et al., , 2012 Pellegrino et al., 2014; Rauthan et al., 2013; Tian et al., 2016) . In mammalian cells, we reported a SIRT3-dependent axis of the UPR mt that activates antioxidant genes, mitochondrial biogenesis, and mitophagy (Kenny and Germain, 2017a, 2017b; Kenny et al., 2017a Kenny et al., , 2017b Papa and Germain, 2014) . A strikingly similar sirtuin UPR mt axis exists in C. elegans (Mouchiroud et al., 2013) . Recently, mitohormesis was described in mammalian cells using an inducible and reversible SOD2 knockdown mouse (iSOD2-KD) (Cox et al., 2018) . In this study, knockdown of SOD2 in development caused increased ROS and mitohormesis, resulting in mitochondrial biogenesis and antioxidant programs (Cox et al., 2018) .
In the context of development and aging, mitohormesis in the absence of underlying pathology is beneficial. In the context of cancer, however, the persistent activation of cytoprotective mechanisms by mitohormesis may favor tumor growth and progression. We initiated the current study to determine if mitohormesis occurs under endogenous oxidative stress in breast cancer and to assess its potential impact on disease progression.
Our data suggest the existence of two subpopulations of cancer cells characterized by mitochondrial ROS levels. We found that the ROS-positive subpopulation upregulates mitoprotective pathways, such as the UPR mt , which maintain ROS in the hormetic zone and result in increased mitochondrial fitness in a manner consistent with mitohormesis. Consequently, these cells are more resistant to oxidative stress and have increased metastatic capacity. Our data suggest that cancer cells exploit mitohormesis to enhance metastatic disease progression.
RESULTS

Mitohormesis in Primary Tumors Identifies a Metastatic Subset of Cancer Cells
Two cohorts of 3-month-old female MTTV-rtTA/TetO-NeuNT mice (Moody et al., 2002) were given doxycycline supplemented drinking water to generate primary mammary tumors at different rates ( Figure 1A ). Using MitoSOX, flow cytometry was performed on primary tumors from all mice, and a distinct biphasic distribution of mitochondrial ROS was observed (Figures 1B and 1C) . Low (ROSÀ) and high ROS (ROS+) subpopulations were isolated by fluorescence-associated cell sorting (FACS) and expanded ex vivo ( Figure 1C ). By transwell invasion assay, we found the ROS+ subpopulation significantly more invasive than its matched ROSÀ counterpart ( Figure 1D ). Further, we found that this difference is maintained over continued passage, indicating a stable phenotype ( Figure 1D ). This was not due to different proliferation rates ( Figure S1A ). After confirming no intrinsic differences in bioluminescence ( Figure S1B ), we performed tail vein injections to test metastasis differences in vivo. We found that ROS+ cells were significantly more metastatic than the ROSÀ subpopulation (Figures 1E and 1F) . As ROS activates the UPR mt (Papa and Germain, 2014) and correlates with an invasive phenotype (Kenny et al., 2017a), we probed both subpopulations directly after FACS ( Figure 1C ) for markers of the UPR mt ( Figure 1G ). We found the ROS+ subpopulation upregulates UPR mt markers, including the SIRT3 axis (SIRT3, FOXO3a, LC3, NRF1, SOD2) and the CHOP/ATF5 axis (HSP60) ( Figure 1D ). Using an unbiased multi-omic approach, SOD1 was identified as a part of the UPR mt (M€ unch and Harper, 2016) . We therefore included SOD1 and also found it upregulated in ROS+ cells ( Figure 1G ). To test if mitohormesis was occurring, we assessed mitochondrial ROS levels following ex vivo expansion ( Figure 1H ). Consistent with persistent activation of cytoprotective mechanisms by mitohormesis, we found the original ROS+ subpopulation had significantly lower levels of ROS ( Figure 1H ), suggesting that this subpopulation is resistant to oxidative stress from ex vivo growth. We then isolated the ROSÀ portion of the original subpopulations by FACS to query activation of the UPR mt under lower levels of oxidative stress ( Figure 1H ). We found that the original ROS+ subpopulation still had enhanced activation of the UPR mt ( Figure 1I ). This observation supports the conclusion that oxidative stress in primary tumors induces mitohormesis in a population of cells. To functionally demonstrate the consequence of mitohormesis, we subjected the original ROSÀ and ROS+ subpopulations to an oxidative stress challenge using menadione-a redox cycling compound that promotes mitochondrial ROS production and mitochondrial stress (Cox et al., 2018) . We found that the ROS+ subpopulation was significantly more resistant to cell death by menadione than its ROSÀ counterpart ( Figure 1J ). Taken Figure S1C ), we first established that doxycycline alone does not activate the UPR mt (Figures S1D-S1F; see STAR Methods). We then used immunohistochemistry (IHC) to monitor UPR mt activation in primary tumors and lung metastases of these mice. In primary tumors, we found heterogeneous staining of all UPR mt markers ( Figure 2A ). This suggests that the UPR mt is focally activated in primary tumors under endogenous stress. Further, we found that all markers of the UPR mt except FOXO3a were increased in lung metastases compared with primary tumors ( Figure 2B ), indicating in vivo that metastatic cells activate the UPR mt . Using overlaid serial sections stained by IHC, we found that all markers of the UPR mt co-localize in primary tumors ( Figure 2C ) and metastatic lesions ( Figure 2D (Kenny et al., 2017a) . Having established that endogenous mitohormesis primed a subpopulation of cancer cells in vivo to become more invasive, we hypothesized that the invasive subpopulation of a given cell line should have increased UPR mt activation. To test this possibility, we performed a transwell invasion assay with MCF7 cells and isolated the invasive subpopulation, MCF7 iteration 1 (I1) ( Figure 3A ). As expected, MCF7 I1 cells were more invasive than the parental ( Figure 3B ). When mitochondrial ROS levels were compared, MCF7 I1 cells had less than the parental, consistent with mitohormesis (Figure 3C ). Importantly, MCF7 I1 cells had more UPR mt activation ( Figure 3D ). We also analyzed levels of NRF2, as it is a master transcription factor for antioxidant genes and binds to the promoter of SIRT3 (DeNicola et al., 2011; Hayes and McMahon, 2006; Padmanabhan et al., 2006; Satterstrom et al., 2015) . Compared with parental, MCF7 I1 had more NRF2 ( Figure S2A ).
Having demonstrated low and high ROS subpopulations in primary tumors, we asked if this was true in MCF7 cells. We identified and isolated a small ROS+ subpopulation of MCF7 by FACS ( Figure 3E ). We found that the ROS+ subpopulation was significantly more invasive than the parental ( Figure 3F ) and had increased activation of the UPR mt-SIRT3 but not HSP60 or SOD1 ( Figure 3G ). To further test these observations, we repeated the same analyses in invasive, UPR mt-SIRT3 positive MDA-MB-231 cells.
Two consecutive rounds of invasion were used to generate Figure S1 and Table S6 .
(legend on next page)
MDA-MB-231 I1 and I2 cells ( Figure 3H ). We found that MDA-MB-231 I1 and I2 were progressively more invasive than the parental ( Figure 3I ) and had decreased ROS ( Figure 3J ). Consistent with mitohormesis, MDA-MB-231 I1 and I2 showed successive increases in the UPR mt ( Figure 3K ). We also queried NRF2 levels and observed cumulative increases in the invasive subpopulations ( Figure S2B ). When we isolated the ROS+ of MDA-MB-231 cells by FACS ( Figure 3L ), we again found that the ROS+ subpopulation was more invasive than the parental (Figure 3M) . Additionally, ROS+ MDA-MB-231 had enhanced UPR mt activation compared with the parental, except for HSP60 (Figure 3N ). To test if mitohormetically primed cells are resistant to oxidative stress, we again used menadione. As before (Figure 1J) , we found that MDA-MB-231 I1, I2, and ROS+ cells were more resistant to cell death than the parental ( Figure S2C ). To address causality between ROS reduction by UPR mt activation and the invasive phenotype, we treated parental MDA-MB-231 with the antioxidant N-acetyl-L-cysteine (NAC) and compared invasion with parental and I2 cells without NAC (Figure S2D ). We found that treatment with NAC significantly increased invasion of MDA-MB-231 parental cells in comparison to the control but not to the same level as I2 cells ( Figure S2D ). We conclude that reduction of ROS by UPR mt activation promotes invasion but cannot alone explain the phenotype. We therefore used gamitrinib-triphenylphosphonium (G-TPP), a compound shown to activate the UPR mt (Kang et al., 2009; M€ unch and Harper, 2016; Papa and Germain, 2014) to exogenously activate the UPR mt and analyze invasion capacity.
When treated with 5 mM G-TPP, MDA-MB-231 showed robust activation of all UPR mt markers ( Figure S2E ) and enhanced invasion capacity ( Figure S2F ) compared with DMSO control. These results demonstrate that UPR mt activation promotes invasion.
To address causality between UPR mt activation and invasion mechanistically, we performed small interfering RNA (siRNA) knockdown of SIRT3 in MDA-MB-231. SIRT3 knockdown leads to a subsequent decrease of UPR mt-SIRT3 markers (FOXO3a, SOD2, NRF1) but not SOD1 or HSP60 ( Figures 3O and 3P ). Interestingly, SIRT3 knockdown significantly increased LC3, suggesting a potential non-SIRT3-mediated mechanism of upregulation to maintain viability after UPR mt-SIRT3 knockdown ( Figures   3O and 3P) . Importantly, transwell assays of MDA-MB-231 treated with siSIRT3 or non-targeting control revealed that SIRT3 knockdown significantly reduced invasion ( Figure 3Q ). The inhibitory effect of SIRT3 knockdown on invasion was validated using a second siRNA ( Figures S2A and S2B ). Additionally, SIRT3 knockdown did not affect proliferation ( Figure S2C ) or viability ( Figure S2D ), demonstrating a specific effect on invasion. To assess the role of SIRT3 in metastasis in vivo, we generated stable control (shScrambled) and SIRT3 knockout (shSIRT3-345 and shSIRT3-752) MDA-MB-231 cells ( Figure 3R ). Western blotting of these cells confirmed near complete loss of SIRT3 in shSIRT3-345 and shSIRT3-752 compared to shScrambled and ubiquitous GFP expression in all three lines ( Figure 3R ). We queried in vitro invasion capacity of these cells and found that SIRT3 loss reduced invasion capacity (Figure S2K) without impacting in vitro proliferation ( Figure S2L ), as in our siRNA experiments ( Figures 3Q and S2I ). We then performed tail vein injections with these cells and harvested 4 weeks later. Two-photon microscopy was used on freshly excised lungs to visualize GFP+ metastases. While disseminated cells could be identified in all three experimental groups, markedly larger metastatic lesions were detected in shScrambled compared with either shSIRT3 group ( Figures 3S and S2M ). These results indicate that SIRT3 is necessary for overt lung metastasis formation. Whole lung sections were stained by immunofluorescence (IF) for GFP to quantify single disseminated cells, clusters, and micro-metastases. As observed by twophoton microscopy, the shScrambled group had appreciably more multi-cellular lesions than either shSIRT3 group by IF (Figures 3T and S2N) . Importantly, we found significantly more metastatic lesions irrespective of size in shScrambled mice compared with shSIRT3-345 or shSIRT3-752 ( Figures 3T and  S2N ). This suggests that SIRT3 promotes the invasion and extravasation capacity of metastatic breast cancer cells at secondary organs. Taken together, these results demonstrate that SIRT3 is necessary for multiple steps of the metastatic cascade.
UPR mt Gene Signature Identifies Breast Cancer Patients with Worse Prognoses and Mitohormetic Transcriptional Profiles
To address the translational relevance of our findings to patients, we took advantage of publicly available primary breast cancer expression datasets. In a cohort of 1809 patients (Gyö rffy et al., 2010), we extracted expression levels of SIRT3, FOXO3a, SOD2, SOD1, LC3B, NRF1, and HSP60 and computed an average UPR mt expression score per patient ( Figure 4A ). We found a clear subset of patients with higher expression of all markers and called them UPR mt-HIGH ( Figure 4A ). Treating URP mt score as a categorical value, we found a significant association between UPR mt-HIGH and estrogen receptor (ER)-negative disease ( Figure 4A ). This association was also significant when UPR mt score was treated as a continuous variable ( Figure S3A ). UPR mt score was also calculated in the The Cancer Genome Atlas (TCGA) breast cancer cohort and again showed a significant association between ER-negative disease and elevated UPR mt ( Figure S3B ). The molecular classifications in the TCGA cohort enabled comparison of UPR mt among PAM50 intrinsic subtypes ( Figure S3C ). We found that the UPR mt scores were significantly different between breast cancer subtypes, with basal-like and HER2-Enriched having significantly higher levels than luminal A and luminal B ( Figure S3C ). We then assessed the impact of UPR mt expression on outcomes using the larger Kaplan-Meier (KM) plotter cohort (Lá nczky et al., 2016) . Alone, the individual UPR mt genes had mixed prognostic value (Figures S3D-S3J). A multigene classifier of these 7 genes was used to compare clinical outcomes between UPR mt-HIGH and UPR mt-LOW patients. We found that UPR mt-HIGH patients had significantly worse overall survival (Figure 4B) , relapse-free survival ( Figure 4C ), and distant metastasisfree survival ( Figure 4D ) compared with UPR mt-LOW patients. Even in lymph node-positive patients, a population which is at significant increased risk of metastatic relapse, UPR mt-HIGH patients had significantly worse distant metastasis-free survival ( Figure 4E ). To further understand differences between UPR mt-HIGH and UPR mt-LOW patients, we compared global gene expression between the groups. Differential gene expression analysis between UPR mt-HIGH and UPR mt-LOW patients identified 141 genes with a log2 fold change R ±0.6 and a false discovery rate <0.05 (Figure 4F; Tables S1 and S2 ). Transcripts significantly upregulated in UPR mt-HIGH patient tumors included metalloproteases (MMP1, ADAM15, MM7, MMP12) and immune-related genes, such as MARCO ( Figure 4F ; Tables S1 and S2) . MARCO identifies a subset of tumor-associated macrophages that promotes tumor growth and metastatic dissemination (Georgoudaki et al., 2016). Of interest, PDK1
was significantly increased in UPR mt-HIGH patients ( Figure 4F ). PDK1 was also upregulated in the livers of mitohormetically primed iSOD2-KD mice (Cox et al., 2018) . Transcripts significantly downregulated in UPR mt-HIGH patient tumors include the metabolic enzyme MGAM, and PTHLH, which is implicated in epithelial-mesenychmal interactions in the developing mammary gland ( Figure 4F ; Tables S1 and S2).
To understand the gene expression programs differing between UPR mt-HIGH and UPR mt-LOW patients, we performed preranked gene set enrichment analysis (GSEA) ( Table S3 ; Subramanian et al., 2005) . We found that cholesterol homeostasis, cell cycle, and peroxisome proliferator-activated receptor (PPAR) signaling were positively enriched in UPR mt-HIGH patients ( Figure 4G ; Table S4 ). PPAR signaling was identified as the defining transcriptional signature of mitohormetically primed iSOD2-KD mice (Cox et al., 2018) . In addition, mTORC1 signaling and glycine, serine, and threonine metabolism were positively enriched in UPR mt-HIGH patients, in agreement with data that these pathways are activated by mitochondrial stress (Quiró s et al., 2017) . Interestingly, it has been shown that mTORC1 regulates SOD1 activity (Tsang et al., 2018) and HSP60 as part of the mitochondrial integrated stress response (ISRmt) (Khan et al., 2017) . This highlights the integrated nature of mitochondrial stress responses and substantiates the UPR mt as a complex network of signaling axes. Importantly, metastasis, angiogenesis, and cell migration gene sets were positively enriched in UPR mt-HIGH patients ( Figure 4G ; Table S4 ). Innate immunity and inflammation-related gene sets were also positively enriched, in agreement with observations in C. elegans that linked the UPR mt to innate immunity (Pellegrino et al., 2014) ( Figure 4G ; Table S4 ).
Conversely, we found processes related to protein production, such as translational elongation and the ribosome, negatively enriched in UPR mt-HIGH patients ( Figure 4G ; Table S5 ). This is consistent with work showing translational inhibition in response to mitochondrial stress (M€ unch and Harper, 2016; Ruan et al., 2017; Wrobel et al., 2015) . Taken together, these results demonstrate that UPR mt activation is observed in patient samples and is significantly associated with worse clinical outcomes including metastasis. Further, we found that the global gene expression of UPR mt-HIGH patients is indicative of mitohormetic priming and persistent cytoprotective mechanisms.
DISCUSSION
The mitochondria of cancer cells show profound reprogramming and elevated ROS. ROS levels in cancer must be maintained to ensure viability. The ability of ROS manipulation to impact tumor biology is supported by studies demonstrating that antioxidants promote cancer growth and metastasis (Bjelakovic and Gluud, 2007; Le Gal et al., 2015; Sayin et al., 2014) .
Here, we provide evidence that mitohormesis, a phenomenon normally associated with health and longevity, is perniciously used by cancer cells to promote tumor progression. Mitohormesis in cancer cells results in persistent activation of the UPR mt and reduction in oxidative stress. Resultantly, mitohormetically primed cancer cells are more metastatic. The molecular mechanisms underlying mitohormetic activation and UPR mt persistence Negative, white; positive, black. Significant correlation: ER negative and UPR mt-HIGH . Pearson's chi-square, Yates' continuity correction, p = 2.45e-20, n = 1231.
(B) Kaplan-Meier (KM) analysis of overall survival (OS) with UPR mt classifier (n = 1402). HR = hazard ratio.
(C) KM of relapse-free survival (RFS) with UPR mt classifier (n = 3951).
(D) KM of distant metastasis-free survival (DMFS) with UPR mt classifier (n = 1764).
(E) KM of RFS in lymph node positive patients with UPR mt classifier (n = 1133).
(F) Volcano plot UPR mt-HIGH versus UPR mt-LOW patients (n = 1809). Log2 fold change versus false discovery rate (FDR). Significant genes, red (FDR < 0.05 & log2
fold change R ±0.6) (G) Gene set enrichment analysis (GSEA) of UPR mt-HIGH versus UPR mt-LOW (n = 1809). Negatively (left) and positively (right) enriched gene ontology terms. Bar length, normalized enrichment score (NES). Bar color, FDR. Gene set source, color code. See also Figure S3 and Tables S1, S2 , S3, S4, and S5.
in cancer remains elusive. A likely possibility is that epigenetic regulation is involved, as shown in C. elegans (Ma et al., 2019; Merkwirth et al., 2016; Tian et al., 2016 (Riar et al., 2017) . This observation suggests that mitohormesis, which we show promotes tumor progression, is predicted to oppose neurodegeneration.
In the context of cancer biology, our results are also in agreement with numerous studies reporting mitochondrial changes in recurrent tumors and circulating cancer cells. These changes included oxidative phosphorylation, mitochondrial biogenesis, and SOD2 and PGC-1a upregulation, although a unifying mechanism was not identified (Hu et al., 2012; LeBleu et al., 2014; Viale et al., 2014) . The results of our study suggest that activation of the UPR mt-SIRT3 mechanistically underlies these observations. This possibility is further supported by the fact that SIRT3 is a common denominator linking mitochondrial biogenesis, PGC1a, and SOD2. SIRT3 directly controls the activity of SOD2 through deacetylation (Lombard et al., 2007; Tao et al., 2010) . PGC1-a, in complex with ERRa regulates several genes involved in mitochondrial biogenesis as well as SOD2 and SIRT3 (Kong et al., 2010; Giralt et al., 2011) . SIRT3 indirectly regulates PGC1-a through AMPK signaling, which promotes CREB phosphorylation and PGC1a expression (Shi et al., 2005) . Therefore, SIRT3 and PGC1a crosstalk establishes a positive feedback loop to regulate mitochondrial biogenesis and antioxidant defenses. In this study, the transcriptional signature of UPR mtHIGH patients was significantly enriched for PPAR signaling, of which PGC1a is a key component. Notably, the PPAR signaling pathway and PGC1a were key differences seen in mitohormetically primed mice (Cox et al., 2018) . In cancer biology, SIRT3 has been reported to act as an oncogene (Alhazzazi et al., 2011; Cheng et al., 2013; Choi et al., 2016; Cui et al., 2015; George et al., 2016; Li et al., 2010; Papa and Germain, 2014; Wang et al., 2015; Wei et al., 2013) , 2014; Wei et al., 2013; Yu et al., 2016; Zhang and Zhou, 2012) . This discrepancy suggests that the function of SIRT3 in cancer is context dependent. Loss of SIRT3 during tumor formation leads to increased ROS levels and promotes mitochondrial reprogramming (Finley et al., 2011) . Importantly, SIRT3 loss is heterozygous, suggesting selective pressure to maintain an intact copy of the gene (Finley et al., 2011) . When the prognostic value of individual UPR mt genes was analyzed, elevated SIRT3 was associated with better relapse-free survival ( Figure S3F ), in agreement with a recent report (Lee et al., 2018) . This observation is consistent with a study demonstrating that SIRT3 overexpression in MDA-MB-231 cells delays tumor growth in xenografts (Gonzalez Herrera et al., 2018) . It is important to note that this overexpression far exceeds the endogenous levels found in invasive cells, such as MDA-MB-231. The same group also demonstrated that SIRT3 is downregulated in the invasive front of MCF10A cells (Lee et al., 2018) . To reconcile these observations, we propose the following model ( Figure S4 ). In normal cells, SIRT3 levels are highest. This is supported by the observation that MCF10A cells have significantly higher SIRT3 levels than breast cancer cells lines (Papa and Germain, 2014) . During transformation, heterozygous SIRT3 loss increases ROS, which stabilizes HIF1a and produces a glycolytic switch (Brunelle et al., 2005; Chandel et al., 1998 Chandel et al., , 2000 Finley et al., 2011; Haigis et al., 2012) . During tumor progression, however, the retained SIRT3 allele is used to promote invasion and metastasis.
In conclusion, we demonstrate that endogenous mitohormesis leads to persistent activation of the UPR mt in a subset of cancer cells. Consistent with the pro-longevity effect of mitohormesis, its activation leads to global changes in cytoprotective mechanisms, which results in resistance to subsequent stress. In the context of cancer, however, mitohormesis promotes metastatic disease progression.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture MDA-MB-231 and MCF7 cells, and their respective sub-lines were cultured in DMEM media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). LentiX-293T cells (Takara Clonetech) were cultured in DMEM media supplemented with 10% FBS and 1% P/S. Cells derived from MMTV-rtTA/TetO-NeuNT mammary tumors were grown in DMEM / F12 (50/50) supplemented with 10% FBS, 1% P/S, 25 ng/mL Hydrocortisone, 0.25 mg/mL Amphotericin B, and 2 mg/mL Doxycycline and cultured on collagen coated plates (50 mg/mL Collagen 1 rat tail in 0.01M HCL).
Animals
All animal experiments were performed under an IUCAC approved protocol. MMTV-rtTA/TetO-NeuNT mice were originally generated and kindly provided by Lewis Chodosh. Genotypes of mice were confirmed using the following primers: rtTA (5 0 -TGCCGCCAT TATTACGACAAGC-3 0 ; 5 0 -ACCGTACTCGTCAATTCCAAGGG-3 0 ) and Neu: (5 0 -TTTCCTGCAGCAGCCTACGC-3 0 , 5 0 -CGGAACCCA CATCAGGCC-3 0 ). Experimental MMTV-rtTA/TetO-NeuNT were 12-week-old females. Non-transgenic FVBN and C57BL/6N were also used in this study. Experimental FVBN mice were 8-week-old females. Experimental C57BL/6N mice were 8-week-old males. Female Athymic Nude-Foxn1 nu mice 9 or 12 weeks of age were used for tail vein injection experiments. All mice were housed in vivariums at Mount Sinai with ad libitium access to food and water.
METHOD DETAILS siRNA Transfection
Transfections were performed for 72 hours on cells seeded in antibiotic-free medium using Lipofectamine RNAi Max (Invitrogen 13778-100) and Opti-MEM (GIBCO) following manufacturer recommendations. Transfections were performed with non-targeting DsiNC1 (IDT #51-01-14-03) or SIRT3 targeting siRNA: siSIRT3 #1 (5'-GCCCAACGUCACUCACUACTT À3 0 , 5 0 -GUAGUGAGUGAC GUUGGGCTT-'3; GeneLink) and siSIRT3 #2 (5'-ACUCCCAUUCUUCUUUCACTT-3 0 , 5 0 -GUGAAAGAAGAAUGGGAGUTT-3 0 ; GeneLink). Percent of cells alive and total cell number were determined using the Countess automated cell counter and tryphan blue (Invitrogen) on MDA-MB-231 cells treated with siNC1, siSIRT3 #1, or siSIRT3 #2 after 72 hours transfection to determine viability and in vitro proliferation ( Figure S2 ).
Generation of stable shRNA cell lines A pre-designed shRNA vector set was purchased from Biosettia with shRNAs designed against SIRT3 (Gene ID 23410; Accession NM_001017524.2) in the pLV-H1-CMV-Green plasmid (Biosettia #SORT-B01). NEB stable competent E. Coli cells (New England BioLabs #C3040) were transformed by heat shock with plasmids obtained from Biosettia. Transformed colonies were picked and expanded under antibiotic selection. Plasmids were prepared from bacterial cultures by Maxiprep (QIAGEN #12165). OptiMEM (GIBCO) and Lipofectamine 2000 (Invitrogen #11668019) were used to transfect 9 mg of pLV-H1-CMV-Green plasmid, 6 mg psPAX2 plasmid (Addgene #12260), and 3 mg pMD2.G plasmid (Addgene #12259) into LentiX 293T packaging cells in antibiotic free medium. pMD2.G and psPAX2 plasmids were generous gifts from Didier Trono. Lentivirus containing media was then collected, filtered and used with polybrene to infect target MDA-MB-231 Parental cells. Transduced cells were selected for using fluorescence associated cell sorting (FACS) to generate stable shRNA cell lines.
Transwell Invasion Assays
Cells were trypsinized and collected in respective serum-free media (see Cell Culture) and pelleted at 2500 rpm for 5 minutes. Cells were resuspended in respective serum-free media and counted using the Countess automated cell counter and tryphan blue (Invitrogen). Equal cell numbers were seeded in respective serum-free media on 8 mm pore size cell culture inserts for 24-well plates (Corning). Prior to seeding cell seeding, cell culture inserts were coated with growth factor reduced matrigel (GIBCO) diluted 1:100 in PBS that was incubated at room temperature for 2 hours and removed. Respective media with 10% FBS was used in the lower chamber and assays were performed for time frames indicated (see Figures) in a tissue culture incubator. Following incubation, invaded cells were fixed, stained using the Hema 3 Manual Staining Stat Pack according to manufacturer's guidelines (Thermo Fisher Scientific), and placed on glass slides with mounting media (Permount). To generate invasive clones of MCF7 and MDA-MB-231 cells, the protocol outlined above was followed except 8 mm pore size cell culture inserts for 6-well plates (Corning) were used and invaded cells were detached by trypsin and subsequently cultured.
Animal Experiments: Tail Vein Injections
For experiments in Figure 1 , 12-week-old female Athymic Nude-Foxn1 nu mice were given doxycycline at a concentration of 1.5 g/L in drinking water 2 weeks prior to tail vein injection and this was continued throughout the experiment. Doxycycline water was changed biweekly. FACS sorted primary tumor subpopulations (ROS-or ROS+) expanded ex vivo were used for tail vein injection. Prior to tail vein injection, the bioluminescence of ROS-and ROS+ subpopulations was confirmed in vitro and was found to be insignificantly different between the two. 5x10 5 cells in 100 mL PBS was injected into the tail vein of each mouse. Five mice per group were injected.
For experiments in Figure 3 , 9-week-old female Athymic Nude-Foxn1 nu mice were used for tail injections. 1x10 6 cells in 100 uL PBS supplemented with 1% FBS were injected into the tail vein of each mouse. Five mice per group were injected.
Histology and Immunohistochemistry (IHC)
Tissue was fixed in 10% formalin (Thermo Fisher Scientific) and then processed and paraffin embedded for sectioning by the Biorepository Core Facility at Mount Sinai. Hematoxylin and eosin (H&E) or unstained paraffin embedded slides were obtained the from the core facility. Serial 5 mm sections were used for all IHC staining. Briefly, sections were deparrafinized and rehydrated in xylene followed by decreasing alcohol gradients. Antigen retrieval was performed for 30 minutes at 95 C in either citrate buffer pH 6 or 10 mM TRIS 1 mM EDTA pH 9. Following antigen retrieval, endogenous peroxidase activity was quenched using Dako Dual Endogenous Enzyme Block (#S20003) followed by serum blocking (MP Biomedicals Normal Antibody Diluent #98063) at room temperature. Primary antibody staining was performed at room temperature or 4 C for an optimized length of time. Secondary antibody staining with either Biotynlated Anti-Rabbit (Jackson ImmunoResearch #711-065-152) or Biotynlated Anti-Mouse (Jackson ImmunoResearch #115-065-205) diluted in TBS was incubated at room temperature for an optimized length of time. Streptavidin-HRP (Vector Labs #SA-5004) was diluted in TBS and incubated for 30 minutes at room temperature. All washes were performed with TBS with 0.04% Tween 20. Antigen detection was performed with freshly prepared AEC Solution (Vector Labs #SK-4200) according to manufacturer guidelines for an optimized length of time. Sections were counterstained with hematoxylin, sufficiently rinsed in water, and mounted in Vectamount aqueous mounting media (Vector Labs #H-5501). For specific conditions used for each antigen staining, see Table S6 .
Sequentially sectioned (5 mm apart) primary tumors and lungs were stained with all indicated antibodies and matching regions of interest were imaged at the same magnification using a Zeiss AX10 light microscope. These images were imported into Adobe Photoshop individually and a layer encompassing all positive staining created. This layer was pseduocolored and saved alone. Multiple psuedocolored layers from different stainings were superimposed on one another after proper alignment. These overlays were saved and displayed on a black background to generate the images seen in Figure 2 .
Immunofluorescence Sections were deparaffinized and rehydrated in xylene followed by decreasing alcohol gradients. Antigen retrieval was performed in citrate buffer pH 6 for 20 minutes in the microwave. Blocking was performed with 10% serum in 0.5% Tween-20 PBS for 2 hours at room temperature. Primary antibody (GFP; Santa Cruz sc-9996) staining was performed overnight at 4 C at a concentration of 1:100 in 1% serum 0.5% Tween-20 PBS. Secondary antibody (Alexa Flour 488 goat anti-mouse; Invitrogen #A11001) staining was performed for 2 hours at roomperature at a concentration of 1:250 in 1% serum 0.5% Tween-20 PBS. Finally, sections were stained with DAPi for 20 minutes at room temperature prior to mounting with Flouromount-G (Southern Biotech). All washes were performed in 0.5% Tween-20 PBS. Sections stained following the protocol above with the exception of no primary antibody were used as negative controls. Metastatic lesions were visualized, counted, and imaged using a Leica DM5500 B upright automated microscope.
Multiphoton Microscopy
Freshly excised lungs from mice used in Figure 3 were imaged using an Olympus FV1000 multiphoton microscope with an Olympus 25X 1.05 NA water immersion objective. As previously described (Olmeda et al., 2017) , a Coherent Chameleon Vision II laser was used at 880 nm to excite GFP. Collagen was visualized by second harmonic generation. 512 3 512 images were taken at 12.5 ms/pixel with a Z step-size of 5 mm using a Kalman filter. For all images, the RFP channel was also captured to rule out artifactual autofluorescence.
Bioluminescence Imaging
Given that the MMTV-rtTA/TetO-NeuNT mice have an IRES-Firefly Luciferase sequence downstream of the Tet-inducible NeuNT, we performed whole body bioluminescence imaging on anthymic nude mice that were tail vein injected with isolated MMTV-rtTA/TetONeuNT primary tumor populations expanded ex vivo. Bioluminescence imaging was conducted using the IVIS Spectrum In Vivo Imaging System (Perkin Elmer) in accordance with manufacturer protocols. Mice anesthetized with isoflurane were imaged before and after D-Luciferin (dissolved in PBS) injection intra peritoneally (150mg/kg body weight) at equal exposure times to determine bioluminescence signal. A kinetic study of bioluminescent signal after Luciferin injection was performed to determine peak signal time.
Bioinformatic Analyses
For Kaplan Meier analysis, KM Plotter was used (Gyö rffy et al., 2010; Lá nczky et al., 2016) . The optimal probes to be used for each UPR mt marker were identified using JetSet(Li et al., 2011) and were as follows: SIRT3 (221913_at), FOXO3a (217399_s_at), SOD2 Figure 4A . Welch's two sample t-test, two-sided, p < 2.2e-16; Mean ± SD; n = 1231. B) Mean UPR mt Expression Score was calculated in the TCGA breast cancer cohort and compared between patients with ER Positive and ER Negative disease. Wilcoxon signed-rank test, two-sided, p = 7.2e-11; Mean ± SD; n = 784. C) Mean UPR mt Expression Score in the TCGA breast cancer cohort was compared between breast cancer subtypes identified by PAM50. Kruskal-Wallis test, p = 8.6e-6 , * p < 0.05; **** p < 0.0001; Mean ± SD; n = 1102. D) Kaplan Meier analysis of relapse-free survival in patients with high (33.3% of patients) or low (66.6% of patients) SIRT3 expression (n = 3951, source = KM Plotter, Breast Cancer). HR = hazard ratio. E) As in in (D) with FOXO3a expression. Figure 4 . In normal cells, SIRT3 levels are the highest. Upon transformation, SIRT3 is down-regulated leading to increased ROS levels and a metabolic switch to glycolysis. In invasive cancer cells, SIRT3 is elevated but because the majority of breast cancer cells have only one copy of the SIRT3 gene, this elevation never reach the same levels as in normal cells. 
